Key Drivers
- Gross strength
- Rising leverage
- Weak coverage
AIAI Summary
TGTX's raised revenue outlook validates BRIUMVI demand, but the investment case has shifted to a “show-me” story where durable operating leverage and cash flow must prove out fast, because compressed margins, rising debt, and just 1.6x interest coverage leave little room for execution misses.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross strength
- •Rising leverage
- •Weak coverage
TGTX has strong gross margins and solid liquidity, but weaker earnings quality, rising leverage, and soft near-term profitability make debt service and cash generation the main risks.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support rebound
- •Failed reversal
Over the last month, TGTX remains in a short-term downtrend, with a bounce off $46-$47 and a test of $49-$50, but the stock stays weak until it reclaims the $52-$54 resistance zone.
Sharp drop from $56.04 to $46.17, then a partial rebound
Sentiment & News
Key News Insights:
- •BRIUMVI Surge
- •EPS Miss
- •Legal Overhang
TG Therapeutics posted strong BRIUMVI-driven revenue growth and raised 2026 guidance, but an EPS miss, manufacturing spending, and litigation overhang weighed on the stock.
The update is constructive for long-term sales momentum, but near-term upside may be limited by margin pressure and mixed investor sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings